MAPT and Alzheimer disease: Ideally, new biomarkers should represent Aβ- and tau-independent AD pathology, thereby enabling monitoring of clinical and biological benefits during Aβ- and tau-targeting therapies, in which changes in Aβ- and tau-biomarkers are inevitable.